Table 2.
Clinicopathologic characteristics according to breast cancer phenotype
| Parameters | Total n = 721 (%) | Luminal A n = 302 (%) | Luminal B n = 168 (%) | HER-2 n = 69 (%) | TNBC n = 182 (%) | P-value |
|---|---|---|---|---|---|---|
| n = 302 (%) | n = 168 (%) | n = 69 (%) | n = 182 (%) | |||
| Age (years, mean ± SD) | 49.6 ± 10.9 | 50.6 ± 10.4 | 48.4 ± 10.0 | 52.4 ± 10.0 | 48.0 ± 12.4 | 0.005 |
| Histologic grade | <0.001 | |||||
| I | 120 (16.6) | 92 (30.5) | 20 (11.9) | 1 (1.4) | 7 (3.8) | |
| II | 364 (50.5) | 182 (60.3) | 91 (54.2) | 36 (52.2) | 55 (30.2) | |
| III | 237 (32.9) | 28 (9.3) | 57 (33.9) | 32 (46.4) | 120 (65.9) | |
| Tumor stage | 0.007 | |||||
| T1 | 350 (48.5) | 167 (55.3) | 85 (50.6) | 30 (43.5) | 68 (37.4) | |
| T2 | 356 (49.4) | 127 (42.1) | 81 (48.2) | 38 (55.1) | 110 (60.4) | |
| T3 | 15 (2.1) | 8 (2.6) | 2 (1.2) | 1 (1.4) | 4 (2.2) | |
| Nodal stage | 0.060 | |||||
| N0 | 425 (58.9) | 171 (56.6) | 92 (54.8) | 42 (60.9) | 120 (65.9) | |
| N1 | 192 (26.6) | 89 (29.5) | 43 (25.6) | 13 (18.8) | 47 (25.8) | |
| N2 | 65 (9.0) | 27 (8.9) | 18 (10.7) | 9 (13.0) | 11 (6.0) | |
| N3 | 39 (5.4) | 15 (5.0) | 15 (8.9) | 5 (7.2) | 4 (2.2) | |
| Estrogen receptor status | <0.001 | |||||
| Negative | 261 (36.2) | 5 (1.7) | 5 (3.0) | 69 (100.0) | 182 (0.0) | |
| Positive | 460 (63.8) | 297 (98.3) | 163 (97.0) | 0 (0.0) | 0 (0.0) | |
| Progesterone receptor status | <0.001 | |||||
| Negative | 346 (48.0) | 49 (16.2) | 46 (27.4) | 69 (100.0) | 182 (100.0) | |
| Positive | 375 (52.0) | 253 (83.8) | 122 (72.6) | 0 (0.0) | 0 (0.0) | |
| HER-2 status | <0.001 | |||||
| Negative | 573 (79.5) | 302 (100.0) | 89 (53.0) | 0 (0.0) | 182 (100.0) | |
| Positive | 148 (20.5) | 0 (0.0) | 79 (47.0) | 69 (100.0) | 0 (0.0) | |
| Ki-67 LI (%, mean ± SD) | 17.3 ± 18.4 | 4.7 ± 3.7 | 19.6 ± 12.6 | 19.3 ± 12.8 | 35.1 ± 23.0 | <0.001 |
| Tumor recurrence | 63 (8.7) | 14 (4.6) | 13 (7.7) | 11 (15.9) | 25 (13.7) | 0.001 |
| Patient death | 60 (8.3) | 12 (4.0) | 13 (7.7) | 11 (15.9) | 24 (13.2) | <0.001 |
| Duration of clinical follow-up (months, mean ± SD) | 70.0 ± 31.2 | 72.4 ± 29.3 | 70.2 ± 30.0 | 65.2 ± 34.3 | 67.8 ± 34.2 | 0.234 |
TNBC triple negative breast cancer.